ClinicalTrials.gg
CompletedNCT02031432CORAL XTUpdated Jul 15, 2021Results posted

CORAL XT - Open-label Extension Trial of the CORAL Trial

A Phase 3 interventional study of Cebranopadol in Pain, Neoplasms and Chronic Pain, sponsored by Tris Pharma, Inc.. Completed at 22 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Pain with a site in Bulgaria — none open to participants now, none under way, none of them phase 3. Pain · Bulgaria.

Enrollment
16th of 19
76 · median 397
Started
2013
with 1 other
Phase 3
14 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
3 of 19
Tris Pharma, Inc.

Among the 19 studies in Pain with a site in Bulgaria, this one is the 16th largest by enrollment, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 11th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 19 studies in Pain with a site in Bulgaria is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Pain with a site in Bulgaria as a file.
02

Study summary

The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.

Read the detailed description

The trial consisted of 3 phases: Titration Phase, Maintenance Phase, and Follow-Up. The total duration of the trial was approximately 28 weeks for each individual participant, including the Follow-up. The participants received cebranopadol for a maximum of approximately 26 weeks.

03

Conditions studied

  • Pain
  • Neoplasms
  • Chronic Pain

Keywords

  • cancer-related pain
  • cebranopadol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed indicating that the participant understands the purpose of and procedures required for the trial and is willing to participate in the trial.
  • Participants must be at least 18 years of age at the Enrollment Visit.
  • Women of must have a negative pregnancy test at enrollment and must not be lactating at the Enrollment Visit.
  • Participants must be willing to use medically acceptable and highly effective methods of .
  • Participants who have completed treatment in KF6005/07 and are still in need of around-the-clock pain analgesia with strong opioids.

Exclusion criteria

Exclusion Criteria:

  • The participant has a disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.
  • Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.
  • Participants taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.
  • History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, bradycardia).
  • Concurrent participation in another trial (except participation in KF6005/07) or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial, or previous participation in this trial.
  • Employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Cebranopadol

    Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning. Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day.

    Drug: Cebranopadol

Interventions

  • Film-coated tablet; strengths: 200, 400, or 600 µg

    Also known as: GRT6005

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Event (TEAEs)

    The safety of cebranopadol was assessed by the number of participants with treatment emergent adverse events (TEAEs). A TEAE was any adverse event that occurred after the first administration of investigational medicinal product (IMP), i.e., cebranopadol in this study. In addition, pretreatment adverse events which worsened during the treatment period were also considered TEAEs.

    Time frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose)

Secondary outcomes

  1. Intensity of Treatment Emergent Adverse Events

    A Treatment Emergent Adverse Event (TEAE) was defined as any Adverse Event (AE) that occurred on or after the first intake of cebranopadol or a pretreatment AE which worsened during the treatment period. TEAEs were classified by the investigator as falling into 1 of 3 categories: Mild: Signs and symptoms that can be easily tolerated. Symptoms can be ignored and disappear when the participant is distracted. Moderate: Symptoms cause discomfort but are tolerable; they cannot be ignored and affect concentration. Severe: Symptoms which affect usual daily activity. For TEAE where the intensity changed over time, the maximum intensity observed during the whole duration of the adverse event was documented.

    Time frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow-up after the last dose)

  2. Changes From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period

    Participants were asked "Please rate your pain by selecting the one number that best describes your pain on average during the last week." and scored their average pain intensity during the last week of the treatment period on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The absolute change from baseline for the average pain intensity during the last week was determined for all participants that scored their pain intensities. A mean value for all participants was calculated.

    Time frame: Baseline Visit (Day 1) to End of Treatment Visit (up to 26 weeks).

Other outcomes

  1. Outcome of Treatment Emergent Adverse Events (TEAE)

    The outcome of a TEAE was classified into 1 of the following 6 categories by the investigator, i.e. * Recovered/Resolved. * Recovered/Resolved with sequelae. * Fatal * Recovering/Resolving. * Not recovered/Not resolved. * Unknown (e.g., because the participant is lost to follow up).

    Time frame: Baseline (Day 2) to End of trial (i.e., up to Week 28)

  2. Time to Onset of Treatment Emergent Adverse Events (TEAEs)

    The median time, in days, from the start of the open-label cebranopadol treatment to the start day of the treatment emergent adverse event (TEAE).

    Time frame: Baseline (Day 2) to End of trial (up to Week 28)

  3. Duration of Treatment Emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical occurrence attributed to cebranopadol. Duration of Adverse Event was calculated as stop date minus start date plus 1 for non-missing and partial dates.

    Time frame: Baseline (Day 2) to End of trial (up to Week 28)

  4. Causal Relationship of Treatment Emergent Adverse Events (TEAEs)

    The causality of TEAEs was assessed by the investigator as falling into 1 of the following 7 categories: Conditional/Unclassified, Unassessable/Unclassifiable, Not related, Unlikely, Possible, Probable/likely, or Certain. The numbers of TEAEs per category are presented.

    Time frame: Baseline (Day 2) to End of trial (up to Week 28)

  5. Countermeasures Taken for Treatment Emergent Adverse Events (TEAEs)

    The countermeasure of a Treatment Emergent Adverse Event (TEAE) was classified by the investigator as being a study medication-related countermeasure and based on non-study medication countermeasures. Non-study medication related countermeasures were categorized as being one of the following: No countermeasure given; A newly started medication or change in dose or route of application of a concomitant medication due to the AE; Other countermeasures, e.g., physical therapy, surgery. Study medication-related countermeasures were categorized as being one of the following: Dose not changed; Dose reduced; Drug interrupted; Trial discontinuation. Absolute numbers are per category reported.

    Time frame: Baseline (Day 2) to End of trial (up to Week 28)

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Cebranopadol

    Only participants with TEAEs which were assessed by the investigator as falling into one of the 3 categories of causality (Possible, Probable/likely, or Certain) were summarized. The initial breakdown planned based on intensity, outcome, time to onset, duration, and countermeasures was not performed and is therefore not reported.

    Time frame: Baseline (Day 2) to End of trial (up to Week 28)

  7. Columbia-Suicide Severity Rating Scale (C-SSRS) Scores

    The C-SSRS was administered by a clinician who had been certified to administer the C-SSRS at each visit. Suicidal ideation is classified on a 5-item scale (where 1 = Wish to be dead, 2 = Non-specific active suicidal thoughts, 3 = Active Suicidal Ideation with any methods (not plan) without intent to act, 4 = Active Suicidal Ideation with some intent to act, without specific plan, 5 = Active suicidal ideation with a specific plan and intent). The number of participants with suicidal ideation at baseline is presented below for categories with at least 1 participant.

    Time frame: Baseline (Day 1) to End of trial (up to Week 28)

  8. Mean Scores of Chronic Pain Sleep Inventory (CPSI) and Changes From Baseline

    The CPSI was completed by the participants. It measures 5 items, all on a 100-mm visual analog scale: Participant's assessment of Sleep Problem Index subscores and need for sleep medication (the lower the score the better): (1) Trouble falling asleep (0 = never; 100 = always); (2) Needing sleep medication to help fall asleep (0 = never, 100 = always); (3) Awakened by pain during the night (0 = never, 100 = always); and (4) Awakened by pain in the morning (0 = never, 100 = always). The Sleep Problem Index is the sum of items (1), (3), and (4) with a maximum score of 100 indicating maximum sleep problems. Participant's assessment of the Overall Quality of Sleep (the higher the score the better): (5) Overall quality of sleep (0 = very poor, 100 = excellent).

    Time frame: Baseline (Day 1); End of Treatment (up to Week 26)

  9. Weekly Means of Daily Average Pain Intensity During the First Month of Treatment

    Participants were asked: "Please rate your pain by selecting the one number that best describes your pain on average during the last 24 hours." every day in the morning during the first month of treatment (comprising Titration Weeks 1 and 2 and Maintenance Weeks 1 and 2). They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24-hour average pain intensity was calculated as a mean score of these daily entries of average pain intensity for each week.

    Time frame: Baseline (Day 1); Titration Weeks 1 and 2; Maintenance Weeks 1 and 2

  10. Worst Pain Intensity in the Last Week of Treatment (Week 26)

    Participants were asked: "Please rate your pain by selecting the one number that best describes your pain at its worst during the last week." at some of the visits during the treatment period. They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The mean scores of the worst pain intensity were calculated for all participants. Results for baseline and Week 26 are presented.

    Time frame: Baseline (Day 1); End of Treatment (Week 26)

  11. Weekly Average Number of Breakthrough Pain Episodes

    The number of episodes of breakthrough pain during the past week was planned to be collected. However, for some participants, the intensity of breakthrough pain for the past week has been collected instead of the incidence of breakthrough pain events. Since the values of the intensity of breakthrough pain were much higher (maximum of up to 99) than the frequency of pain events, the mean is skewed and cannot be interpreted. The median for the weekly average number of breakthrough pain episodes is less influenced by these values and is reported below.

    Time frame: Baseline (Day 1); End of Treatment (Week 26)

  12. Mean Scores of Neuropathic Pain Symptom Inventory (NPSI)

    Participants with neuropathic pain (determined by the completion of the DN4 \[Douleur Neuropathique\] questionnaire at enrollment) rated their symptoms of neuropathic pain using the NPSI. Ten out of 12 questions (Q1-3, 5, 6, 8-12) are answered on an 11-point numerical scale (NRS) ranging from 0 (no symptom present) to 10 (worst imaginable). The NPSI Total Score was calculated as the sum of the 10 single items scored on the 11-point NRS divided by 100. The mean score is reported on a scale of 0 (no neuropathic pain components present) to 1 (all neuropathic pain components have the maximum imaginable intensity).

    Time frame: Baseline (Day 1); Weeks 2, 6, 14, 18; End of Treatment (up to Week 26)

  13. EuroQol-5 Dimension (EQ-5D) Health Status Index Outcome

    Participants answered 5 questions on the 5 dimensions of the EuroQol-5 Dimension Health Questionnaire: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has 3 possible answers reflecting 3 levels of impact on the quality of life. Each dimension was assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D Health Status Index score between 0 to 1 (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1), the better the health status.

    Time frame: Baseline (Day 1); End of Treatment (up to Week 26)

  14. EuroQol-5 Dimension (EQ-5D) Health Questionnaire - Visual Analog Scale (VAS)

    The EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant-rated scale where a single value is ticked for "Your own health state today" on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline (Day 1); End of Treatment (up to Week 26)

  15. Patient Global Impression of Change (PGIC)

    In the PGIC, participants indicates the perceived change over the treatment period compared to their condition prior to the start of treatment. Participants are requested to choose 1 of 7 categories. Scores range from "very much improved" to "very much worse". The frequency of responses per category are provided.

    Time frame: Baseline (Day 1); End of Treatment (up to Week 26)

  16. Clinical Global Impression of Change (CGIC)

    For the CGIC assessment, the clinician indicates the perceived change in the patient's condition over the treatment period as compared to the patient's condition prior to the start of treatment. The clinician is requested to choose 1 of 7 categories. Categories range from "very much improved" to "very much worse".

    Time frame: Baseline (Day 1); End of Treatment Visit (up to Week 26)

  17. Use of On-demand Opioid Analgesic Medication

    Participants reported the opioid type and amount of an opioid in mg/day used to relieve their breakthrough pain over the time period in the study. The average number of units of on-demand opioid medication administered during the previous day (reported on Day 3) and during the last 3 days (reported at all other visits) were documented. The number of units of on-demand opioid medication administered during the Treatment Period is summarized descriptively over the treatment period.

    Time frame: From Day 3 to End of Treatment (up to Week 26) (13 time points)

  18. Mean Equipotency Ratio of Morphine Sulfate Prolonged Release Compared to Cebranopadol.

    For those participants, who received morphine prolonged release in the CORAL trial (KF6005/07, NCT01964378) and were, thus, switched from morphine prolonged release to cebranopadol in the CORAL XT trial, the equianalgesic doses of morphine prolonged release and cebranopadol was identified.

    Time frame: Baseline (Day 1); End of first month of treatment

  19. Mean Eastern Cooperative Oncology Group Performance Status (ECOG) Scores

    The investigator scores the ECOG performance status for a participant on a 6-point categorical scale as follows: * 0 indicates that a participant is "fully active, able to carry on all pre-disease performance without restriction." * 1 indicates that a participant is "restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work." * 2 indicates that a participant is "ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours." * 3 indicates that a participant is "capable of only limited selfcare, confined to bed or chair more than 50% of waking hours." * 4 indicates that a participant is "completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair." * 5 indicates that a participant is "dead". Mean ECOG performance status scores are calculated for the number of participants with data available.

    Time frame: From Baseline (Day 1) through to End of treatment (up to Week 26) (9 time points)

07

Results

Posted Jan 18, 2020
Limitations and caveats
A limitation is the open-label design of the study. An extrapolation to a population not suffering from cancer-related pain is limited due to the nature of the underlying disorder.

Participant flow

The first participant was enrolled on the 18 Dec 2013 (first dose taken on the 19 Dec 2013 received) and the last participant completed the trial on the 03 May 2016 (last dose taken on the 12 Apr 2016). All participants in this trial completed the maintenance period in the KF6005/07 (NCT01964378) trial.

Participant flow — Overall Study
MilestoneCebranopadol
Started76
Completing the titration phase67
Completing the treatment39
Completed38
Not completed38
Withdrew: Protocol violation1
Withdrew: Lack of efficacy5
Withdrew: Cancer progression2
Withdrew: Withdrawn as forbidden meds required1
Withdrew: Adverse event8
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up1
Withdrew: Inclusion/exclusion criteria not met5
Withdrew: Death10

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Event (TEAEs)

The safety of cebranopadol was assessed by the number of participants with treatment emergent adverse events (TEAEs). A TEAE was any adverse event that occurred after the first administration of investigational medicinal product (IMP), i.e., cebranopadol in this study. In addition, pretreatment adverse events which worsened during the treatment period were also considered TEAEs.

Time frame:
Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Event (TEAEs)
ParticipantsCebranopadol
Number of Participants With Treatment Emergent Adverse Event (TEAEs)64
SecondaryIntensity of Treatment Emergent Adverse Events

A Treatment Emergent Adverse Event (TEAE) was defined as any Adverse Event (AE) that occurred on or after the first intake of cebranopadol or a pretreatment AE which worsened during the treatment period. TEAEs were classified by the investigator as falling into 1 of 3 categories: Mild: Signs and symptoms that can be easily tolerated. Symptoms can be ignored and disappear when the participant is distracted. Moderate: Symptoms cause discomfort but are tolerable; they cannot be ignored and affect concentration. Severe: Symptoms which affect usual daily activity. For TEAE where the intensity changed over time, the maximum intensity observed during the whole duration of the adverse event was documented.

Time frame:
Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow-up after the last dose)
Reported as:
Number · Number of TEAEs
Intensity of Treatment Emergent Adverse Events
Number of TEAEsCebranopadol
Mild intensity242
Moderate intensity300
Severe intensity119
SecondaryChanges From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period

Participants were asked "Please rate your pain by selecting the one number that best describes your pain on average during the last week." and scored their average pain intensity during the last week of the treatment period on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The absolute change from baseline for the average pain intensity during the last week was determined for all participants that scored their pain intensities. A mean value for all participants was calculated.

Time frame:
Baseline Visit (Day 1) to End of Treatment Visit (up to 26 weeks).
Reported as:
Mean · units on a scale
Changes From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period
units on a scaleCebranopadol
Changes From Baseline in the Average Pain Intensity in the Last Week During the Treatment Period0.8 ± 2.14
Other pre-specifiedOutcome of Treatment Emergent Adverse Events (TEAE)

The outcome of a TEAE was classified into 1 of the following 6 categories by the investigator, i.e. * Recovered/Resolved. * Recovered/Resolved with sequelae. * Fatal * Recovering/Resolving. * Not recovered/Not resolved. * Unknown (e.g., because the participant is lost to follow up).

Time frame:
Baseline (Day 2) to End of trial (i.e., up to Week 28)
Reported as:
Number · Number of TEAEs
Outcome of Treatment Emergent Adverse Events (TEAE)
Number of TEAEsCebranopadol
Recovered/resolved349
Recovered/resolved with sequelae11
Not recovered/not resolved260
Recovering/resolving14
Fatal11
Unknown16
Other pre-specifiedTime to Onset of Treatment Emergent Adverse Events (TEAEs)

The median time, in days, from the start of the open-label cebranopadol treatment to the start day of the treatment emergent adverse event (TEAE).

Time frame:
Baseline (Day 2) to End of trial (up to Week 28)
Reported as:
Median · days
Time to Onset of Treatment Emergent Adverse Events (TEAEs)
daysCebranopadol
Time to Onset of Treatment Emergent Adverse Events (TEAEs)53.0 (19 to 106)
Other pre-specifiedDuration of Treatment Emergent Adverse Events (TEAEs)

An adverse event is any untoward medical occurrence attributed to cebranopadol. Duration of Adverse Event was calculated as stop date minus start date plus 1 for non-missing and partial dates.

Time frame:
Baseline (Day 2) to End of trial (up to Week 28)
Reported as:
Median · days
Duration of Treatment Emergent Adverse Events (TEAEs)
daysCebranopadol
Duration of Treatment Emergent Adverse Events (TEAEs)9.0 (3 to 27)
Other pre-specifiedCausal Relationship of Treatment Emergent Adverse Events (TEAEs)

The causality of TEAEs was assessed by the investigator as falling into 1 of the following 7 categories: Conditional/Unclassified, Unassessable/Unclassifiable, Not related, Unlikely, Possible, Probable/likely, or Certain. The numbers of TEAEs per category are presented.

Time frame:
Baseline (Day 2) to End of trial (up to Week 28)
Reported as:
Number · Number of TEAEs
Causal Relationship of Treatment Emergent Adverse Events (TEAEs)
Number of TEAEsCebranopadol
Certainly Related0
Possibly Related42
Probably/Likely Related7
Unlikely Related37
Not Related574
Unassessable/Unclassifiable1
Conditional/Unclassifiable0
Other pre-specifiedCountermeasures Taken for Treatment Emergent Adverse Events (TEAEs)

The countermeasure of a Treatment Emergent Adverse Event (TEAE) was classified by the investigator as being a study medication-related countermeasure and based on non-study medication countermeasures. Non-study medication related countermeasures were categorized as being one of the following: No countermeasure given; A newly started medication or change in dose or route of application of a concomitant medication due to the AE; Other countermeasures, e.g., physical therapy, surgery. Study medication-related countermeasures were categorized as being one of the following: Dose not changed; Dose reduced; Drug interrupted; Trial discontinuation. Absolute numbers are per category reported.

Time frame:
Baseline (Day 2) to End of trial (up to Week 28)
Reported as:
Number · Number of TEAEs
Countermeasures Taken for Treatment Emergent Adverse Events (TEAEs)
Number of TEAEsCebranopadol
No countermeasure361
Newly started medication281
Other19
Cebranopadol dose not changed as countermeasure595
Cebranopadol dose reduced5
Cebranopadol treatment interrupted14
Cebranopadol withdrawn23
Cebranopadol to dosing missing24
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Cebranopadol

Only participants with TEAEs which were assessed by the investigator as falling into one of the 3 categories of causality (Possible, Probable/likely, or Certain) were summarized. The initial breakdown planned based on intensity, outcome, time to onset, duration, and countermeasures was not performed and is therefore not reported.

Time frame:
Baseline (Day 2) to End of trial (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Cebranopadol
ParticipantsCebranopadol
Participants with related TEAEs20
Participants with related serious TEAEs1
Participants without related TEAEs55
Other pre-specifiedColumbia-Suicide Severity Rating Scale (C-SSRS) Scores

The C-SSRS was administered by a clinician who had been certified to administer the C-SSRS at each visit. Suicidal ideation is classified on a 5-item scale (where 1 = Wish to be dead, 2 = Non-specific active suicidal thoughts, 3 = Active Suicidal Ideation with any methods (not plan) without intent to act, 4 = Active Suicidal Ideation with some intent to act, without specific plan, 5 = Active suicidal ideation with a specific plan and intent). The number of participants with suicidal ideation at baseline is presented below for categories with at least 1 participant.

Time frame:
Baseline (Day 1) to End of trial (up to Week 28)
Reported as:
Count of participants · Participants
Columbia-Suicide Severity Rating Scale (C-SSRS) Scores
ParticipantsCebranopadol
No suicidal ideation or behaviour74
Wish to be dead1
Non-specific active suicidal thoughts1
Other pre-specifiedMean Scores of Chronic Pain Sleep Inventory (CPSI) and Changes From Baseline

The CPSI was completed by the participants. It measures 5 items, all on a 100-mm visual analog scale: Participant's assessment of Sleep Problem Index subscores and need for sleep medication (the lower the score the better): (1) Trouble falling asleep (0 = never; 100 = always); (2) Needing sleep medication to help fall asleep (0 = never, 100 = always); (3) Awakened by pain during the night (0 = never, 100 = always); and (4) Awakened by pain in the morning (0 = never, 100 = always). The Sleep Problem Index is the sum of items (1), (3), and (4) with a maximum score of 100 indicating maximum sleep problems. Participant's assessment of the Overall Quality of Sleep (the higher the score the better): (5) Overall quality of sleep (0 = very poor, 100 = excellent).

Time frame:
Baseline (Day 1); End of Treatment (up to Week 26)
Reported as:
Mean · units on a scale
Mean Scores of Chronic Pain Sleep Inventory (CPSI) and Changes From Baseline
units on a scaleCebranopadol
Baseline - Trouble falling asleep10.0 ± 18.00
End of Treatment - Trouble falling asleep11.7 ± 22.91
Baseline - Need for sleep medication9.2 ± 24.93
End of Treatment - Need for sleep medication10.7 ± 28.53
Baseline - Woken up by pain during night12.5 ± 21.02
End of Treatment - Woken up by pain during night15.3 ± 26.36
Baseline - Woken by pain in the morning12.6 ± 20.71
End of Treatment - Woken by pain in the morning17.5 ± 28.21
Baseline - Overall quality of sleep74.0 ± 27.91
End of Treatment - Overall quality of sleep71.3 ± 30.97
Baseline - Sleep Problem Index35.0 ± 54.03
End of Treatment - Sleep Problem Index44.5 ± 71.10
Other pre-specifiedWeekly Means of Daily Average Pain Intensity During the First Month of Treatment

Participants were asked: "Please rate your pain by selecting the one number that best describes your pain on average during the last 24 hours." every day in the morning during the first month of treatment (comprising Titration Weeks 1 and 2 and Maintenance Weeks 1 and 2). They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24-hour average pain intensity was calculated as a mean score of these daily entries of average pain intensity for each week.

Time frame:
Baseline (Day 1); Titration Weeks 1 and 2; Maintenance Weeks 1 and 2
Reported as:
Mean · units on a scale
Weekly Means of Daily Average Pain Intensity During the First Month of Treatment
units on a scaleCebranopadol
Baseline2.96 ± 1.890
Titration Week 13.18 ± 1.795
Titration Week 22.90 ± 1.838
Maintenance Week 12.73 ± 1.848
Maintenance Week 22.69 ± 1.843
Other pre-specifiedWorst Pain Intensity in the Last Week of Treatment (Week 26)

Participants were asked: "Please rate your pain by selecting the one number that best describes your pain at its worst during the last week." at some of the visits during the treatment period. They scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The mean scores of the worst pain intensity were calculated for all participants. Results for baseline and Week 26 are presented.

Time frame:
Baseline (Day 1); End of Treatment (Week 26)
Reported as:
Mean · units on a scale
Worst Pain Intensity in the Last Week of Treatment (Week 26)
units on a scaleCebranopadol
Baseline4.3 ± 2.52
End of Treatment (Week 26)5.1 ± 2.89
Other pre-specifiedWeekly Average Number of Breakthrough Pain Episodes

The number of episodes of breakthrough pain during the past week was planned to be collected. However, for some participants, the intensity of breakthrough pain for the past week has been collected instead of the incidence of breakthrough pain events. Since the values of the intensity of breakthrough pain were much higher (maximum of up to 99) than the frequency of pain events, the mean is skewed and cannot be interpreted. The median for the weekly average number of breakthrough pain episodes is less influenced by these values and is reported below.

Time frame:
Baseline (Day 1); End of Treatment (Week 26)
Reported as:
Median · Weekly average number of episodes
Weekly Average Number of Breakthrough Pain Episodes
Weekly average number of episodesCebranopadol
Baseline1.00 (0.0 to 66.0)
End of Treatment (Week 26)1.00 (0.0 to 99.0)
Other pre-specifiedMean Scores of Neuropathic Pain Symptom Inventory (NPSI)

Participants with neuropathic pain (determined by the completion of the DN4 \[Douleur Neuropathique\] questionnaire at enrollment) rated their symptoms of neuropathic pain using the NPSI. Ten out of 12 questions (Q1-3, 5, 6, 8-12) are answered on an 11-point numerical scale (NRS) ranging from 0 (no symptom present) to 10 (worst imaginable). The NPSI Total Score was calculated as the sum of the 10 single items scored on the 11-point NRS divided by 100. The mean score is reported on a scale of 0 (no neuropathic pain components present) to 1 (all neuropathic pain components have the maximum imaginable intensity).

Time frame:
Baseline (Day 1); Weeks 2, 6, 14, 18; End of Treatment (up to Week 26)
Reported as:
Mean · units on a scale
Mean Scores of Neuropathic Pain Symptom Inventory (NPSI)
units on a scaleCebranopadol
Baseline0.243 ± 0.1677
Week 20.200 ± 0.2006
Week 60.146 ± 0.1397
Week 140.150 ± 0.1564
Week 180.117 ± 0.1529
Final Visit (Week 26)0.236 ± 0.2183
Other pre-specifiedEuroQol-5 Dimension (EQ-5D) Health Status Index Outcome

Participants answered 5 questions on the 5 dimensions of the EuroQol-5 Dimension Health Questionnaire: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has 3 possible answers reflecting 3 levels of impact on the quality of life. Each dimension was assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D Health Status Index score between 0 to 1 (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1), the better the health status.

Time frame:
Baseline (Day 1); End of Treatment (up to Week 26)
Reported as:
Mean · units on a scale
EuroQol-5 Dimension (EQ-5D) Health Status Index Outcome
units on a scaleCebranopadol
Baseline0.687 ± 0.2111
Final Visit (Week 26)0.606 ± 0.3214
Other pre-specifiedEuroQol-5 Dimension (EQ-5D) Health Questionnaire - Visual Analog Scale (VAS)

The EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant-rated scale where a single value is ticked for "Your own health state today" on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline (Day 1); End of Treatment (up to Week 26)
Reported as:
Mean · units on a scale
EuroQol-5 Dimension (EQ-5D) Health Questionnaire - Visual Analog Scale (VAS)
units on a scaleCebranopadol
Baseline61.9 ± 20.62
Final Visit (Week 26)56.6 ± 21.94
Other pre-specifiedPatient Global Impression of Change (PGIC)

In the PGIC, participants indicates the perceived change over the treatment period compared to their condition prior to the start of treatment. Participants are requested to choose 1 of 7 categories. Scores range from "very much improved" to "very much worse". The frequency of responses per category are provided.

Time frame:
Baseline (Day 1); End of Treatment (up to Week 26)
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC)
ParticipantsCebranopadol
Very much improved5
Much improved17
Minimally improved15
No change9
Minimally worse8
Much worse3
Very much worse1
Missing4
Other pre-specifiedClinical Global Impression of Change (CGIC)

For the CGIC assessment, the clinician indicates the perceived change in the patient's condition over the treatment period as compared to the patient's condition prior to the start of treatment. The clinician is requested to choose 1 of 7 categories. Categories range from "very much improved" to "very much worse".

Time frame:
Baseline (Day 1); End of Treatment Visit (up to Week 26)
Reported as:
Count of participants · Participants
Clinical Global Impression of Change (CGIC)
ParticipantsCebranopadol
Very much improved9
Much improved25
Minimally improved10
No change5
Minimally worse4
Much worse3
Very much worse3
Missing3
Other pre-specifiedUse of On-demand Opioid Analgesic Medication

Participants reported the opioid type and amount of an opioid in mg/day used to relieve their breakthrough pain over the time period in the study. The average number of units of on-demand opioid medication administered during the previous day (reported on Day 3) and during the last 3 days (reported at all other visits) were documented. The number of units of on-demand opioid medication administered during the Treatment Period is summarized descriptively over the treatment period.

Time frame:
From Day 3 to End of Treatment (up to Week 26) (13 time points)
Reported as:
Mean · units
Use of On-demand Opioid Analgesic Medication
unitsCebranopadol
Day 31.08 ± 1.772
Week 11.45 ± 2.396
Day 111.29 ± 2.280
Week 20.96 ± 1.817
Day 170.64 ± 1.218
Week 30.78 ± 2.126
Week 40.72 ± 1.380
Week 60.59 ± 1.252
Week 100.51 ± 1.044
Week 140.47 ± 1.174
Week 180.55 ± 1.250
Week 220.77 ± 1.641
End of Treatment (up to Week 26)1.06 ± 2.397
Other pre-specifiedMean Equipotency Ratio of Morphine Sulfate Prolonged Release Compared to Cebranopadol.

For those participants, who received morphine prolonged release in the CORAL trial (KF6005/07, NCT01964378) and were, thus, switched from morphine prolonged release to cebranopadol in the CORAL XT trial, the equianalgesic doses of morphine prolonged release and cebranopadol was identified.

Time frame:
Baseline (Day 1); End of first month of treatment
Reported as:
Mean · Ratio
Mean Equipotency Ratio of Morphine Sulfate Prolonged Release Compared to Cebranopadol.
RatioCebranopadol
Mean Equipotency Ratio of Morphine Sulfate Prolonged Release Compared to Cebranopadol.156.8 ± 58.2
Other pre-specifiedMean Eastern Cooperative Oncology Group Performance Status (ECOG) Scores

The investigator scores the ECOG performance status for a participant on a 6-point categorical scale as follows: * 0 indicates that a participant is "fully active, able to carry on all pre-disease performance without restriction." * 1 indicates that a participant is "restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work." * 2 indicates that a participant is "ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours." * 3 indicates that a participant is "capable of only limited selfcare, confined to bed or chair more than 50% of waking hours." * 4 indicates that a participant is "completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair." * 5 indicates that a participant is "dead". Mean ECOG performance status scores are calculated for the number of participants with data available.

Time frame:
From Baseline (Day 1) through to End of treatment (up to Week 26) (9 time points)
Reported as:
Mean · units on a scale
Mean Eastern Cooperative Oncology Group Performance Status (ECOG) Scores
units on a scaleCebranopadol
Baseline1.1 ± 0.75
Week 21.1 ± 0.76
Week 41.1 ± 0.78
Week 61.2 ± 0.74
Week 101.1 ± 0.77
Week 141.1 ± 0.73
Week 181.2 ± 0.91
Week 221.4 ± 0.82
Final Visit (up to Week 26)1.6 ± 1.10

Adverse events

Collected over All AEs were documented from the time of enrollment (i.e., the time the informed consent form was signed) up to the time of the last protocol scheduled contact occurred, i.e., date of last visit/contact (a telephone call in the case of discontinuation). Treatment emergent adverse events (TEAEs) were reported for up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow-up after the last dose).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cebranopadol10/76 (13.2%)32/76 (42.1%)63/76 (82.9%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventCebranopadol
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/76
AnaemiaBlood and lymphatic system disorders3/76
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/76
AstheniaGeneral disorders2/76
ConcussionInjury, poisoning and procedural complications2/76
HaemoptysisRespiratory, thoracic and mediastinal disorders2/76
Anaemia of malignant diseaseBlood and lymphatic system disorders2/76
Superior vena cava syndromeVascular disorders1/76
Aortic thrombosisVascular disorders1/76
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/76
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCebranopadol
AstheniaGeneral disorders19/76
Decreased appetiteMetabolism and nutrition disorders17/76
NauseaGastrointestinal disorders15/76
ConstipationGastrointestinal disorders11/76
FatigueGeneral disorders9/76
Oedema peripheralGeneral disorders9/76
PyrexiaGeneral disorders9/76
HeadacheNervous system disorders8/76
SomnolenceNervous system disorders8/76
Back painMusculoskeletal and connective tissue disorders8/76

Baseline characteristics

Participants who completed treatment in KF6005/07 started on a daily dose of 200 or 400 μg (depending on previous dose level) in KF6005/09. The treatment code from KF6005/07 was not unblinded at the time of cebranopadol treatment initiation in KF6005/09, and in this trial all participants were titrated to their optimal dose of cebranopadol.

Age, Continuous
Age, Continuous(years)Cebranopadol
Mean61.7 ± 9.81
Age, Customized
Age, Customized(Participants)Cebranopadol
Below 18 years0
From 18 to less than 65 years43
From 65 to less than 85 years33
Above 85 years0
Sex: Female, Male
Sex: Female, Male(Participants)Cebranopadol
Female32
Male44
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cebranopadol
White76
Region of Enrollment
Region of Enrollment(participants)Cebranopadol
Romania2
Hungary2
Austria3
Belgium1
Denmark2
Poland17
Slovakia21
Bulgaria4
Serbia4
Germany20
DN4 Neuropathic Pain at start of KF6005/07
DN4 Neuropathic Pain at start of KF6005/07(participants)Cebranopadol
DN4 positive21
DN4 negative55
Height
Height(meter)Cebranopadol
Mean1.684 ± 0.0844
Weight
Weight(kilograms)Cebranopadol
Mean72 ± 14.04

3 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • AT004
    Vienna, 1090, Austria
  • BE001
    Sint-Niklaas, 9100, Belgium
  • BG001
    Shumen, 9700, Bulgaria
  • BG008
    Sofia, 1330, Bulgaria
  • BG003
    Sofia, 1407, Bulgaria
  • BG004
    Sofia, 1407, Bulgaria
  • DK006
    Aalborg, 9000, Denmark
  • DK004
    Herlev, 2730, Denmark
  • DE008
    Böhlen, 4564, Germany
  • DE010
    Munich, 81377, Germany
  • HU011
    Nyiregyhaza, 4400, Hungary
  • PL012
    Będzin, 42-500, Poland
  • PL014
    Dąbrowa Górnicza, 41-300, Poland
  • PL003
    Gdansk, 80-208, Poland
  • PL010
    Gliwice, 44-100, Poland
  • RO002
    Cluj-Napoca, 400015, Romania
  • RS003
    Belgrade, 11000, Serbia
  • RS002
    Sremska Kamenica, 21204, Serbia
  • RS005
    Zrenjanin, 23000, Serbia
  • SK004
    Bratislava, 851 07, Slovakia
  • SK001
    Presov, 08001, Slovakia
  • SK005
    Pruské, 018 52, Slovakia
09

References and documents

Publications

  • Koch ED, Kapanadze S, Eerdekens MH, Kralidis G, Letal J, Sabatschus I, Ahmedzai SH. Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks. J Pain Symptom Manage. 2019 Sep;58(3):390-399. doi: 10.1016/j.jpainsymman.2019.05.012. Epub 2019 May 30. PubMed 31152783 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Apr 2016, 28 months.

Results were first posted in Jan 2020, 3 years 9 months after primary completion.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 28 months is above that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2013
First posted
Jan 9, 2014
StartActual
Dec 18, 2013
Primary completionActual
Apr 2016
CompletionActual
May 3, 2016
Results first posted
Jan 18, 2020
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02031432
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Jan 9, 2014
Start date
Dec 18, 2013
Primary completion
Apr 2016
Completion
May 3, 2016
Results posted
Jan 18, 2020
Last update
Jul 15, 2021

Study contacts

Director Clinical Trials
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion